---
document_datetime: 2025-12-02 05:59:58
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/nyxthracis.html
document_name: nyxthracis.html
version: success
processing_time: 0.1095731
conversion_datetime: 2025-12-27 19:28:51.129372
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Nyxthracis (previously Obiltoxaximab SFL)

[RSS](/en/individual-human-medicine.xml/67368)

##### Withdrawn

This medicine's authorisation has been withdrawn

obiltoxaximab Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Nyxthracis (previously Obiltoxaximab SFL)](#news-on)
- [More information on Nyxthracis](#more-information-on-nyxthracis-70499)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 2 August 2024 the European Commission withdrew the marketing authorisation under exceptional circumstances for Nyxthracis (obiltoxaximab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, SFL Pharmaceuticals Deutschland GmbH, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Nyxthracis was granted marketing authorisation under exceptional circumstances in the EU on 18 November 2020 for treatment of inhalational anthrax due to Bacillus anthracis, in combination with appropriate antibacterial drugs, and for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available. The medicinal product was subject to annual re-assessment of the marketing authorisation under exceptional circumstances.

The European Public Assessment Report (EPAR) for Nyxthracis is updated to indicate that the marketing authorisation is no longer valid.

Obiltoxaximab SFL : EPAR - Medicine overview

Reference Number: EMA/506632/2020

English (EN) (206.75 KB - PDF)

**First published:** 27/11/2020

**Last updated:** 09/09/2024

[View](/en/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-152)

български (BG) (269.92 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/bg/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_bg.pdf)

español (ES) (205.65 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/es/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_es.pdf)

čeština (CS) (248.01 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/cs/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_cs.pdf)

dansk (DA) (202.61 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/da/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_da.pdf)

Deutsch (DE) (215.2 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/de/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_de.pdf)

eesti keel (ET) (196.39 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/et/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_et.pdf)

ελληνικά (EL) (285.5 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/el/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_el.pdf)

français (FR) (213.32 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/fr/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_fr.pdf)

hrvatski (HR) (240.33 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/hr/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_hr.pdf)

italiano (IT) (203.09 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/it/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (252.61 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/lv/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (244.11 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/lt/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_lt.pdf)

magyar (HU) (238.54 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/hu/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_hu.pdf)

Malti (MT) (254.15 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/mt/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_mt.pdf)

Nederlands (NL) (209.84 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/nl/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_nl.pdf)

polski (PL) (244.32 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/pl/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_pl.pdf)

português (PT) (205.11 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/pt/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_pt.pdf)

română (RO) (243.83 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/ro/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_ro.pdf)

slovenčina (SK) (242.26 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/sk/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_sk.pdf)

slovenščina (SL) (242.88 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/sl/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_sl.pdf)

Suomi (FI) (202.64 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/fi/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_fi.pdf)

svenska (SV) (203.15 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/sv/documents/overview/obiltoxaximab-sfl-epar-medicine-overview_sv.pdf)

Obiltoxaximab SFL : EPAR - Risk-management-plan summary

English (EN) (143.32 KB - PDF)

**First published:** 27/11/2020

**Last updated:** 09/09/2024

[View](/en/documents/rmp-summary/obiltoxaximab-sfl-epar-risk-management-plan-summary_en.pdf)

## Product information

Nyxthracis : EPAR - Product information

English (EN) (1.02 MB - PDF)

**First published:** 27/11/2020

**Last updated:** 09/09/2024

[View](/en/documents/product-information/nyxthracis-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-749)

български (BG) (1.39 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/bg/documents/product-information/nyxthracis-epar-product-information_bg.pdf)

español (ES) (1.12 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/es/documents/product-information/nyxthracis-epar-product-information_es.pdf)

čeština (CS) (1.24 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/cs/documents/product-information/nyxthracis-epar-product-information_cs.pdf)

dansk (DA) (1018.43 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/da/documents/product-information/nyxthracis-epar-product-information_da.pdf)

Deutsch (DE) (1.19 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/de/documents/product-information/nyxthracis-epar-product-information_de.pdf)

eesti keel (ET) (1.09 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/et/documents/product-information/nyxthracis-epar-product-information_et.pdf)

ελληνικά (EL) (1.48 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/el/documents/product-information/nyxthracis-epar-product-information_el.pdf)

français (FR) (1.16 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/fr/documents/product-information/nyxthracis-epar-product-information_fr.pdf)

hrvatski (HR) (1.3 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/hr/documents/product-information/nyxthracis-epar-product-information_hr.pdf)

íslenska (IS) (1.02 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/is/documents/product-information/nyxthracis-epar-product-information_is.pdf)

italiano (IT) (1.15 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/it/documents/product-information/nyxthracis-epar-product-information_it.pdf)

latviešu valoda (LV) (1.32 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/lv/documents/product-information/nyxthracis-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.33 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/lt/documents/product-information/nyxthracis-epar-product-information_lt.pdf)

magyar (HU) (1.35 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/hu/documents/product-information/nyxthracis-epar-product-information_hu.pdf)

Malti (MT) (1.4 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/mt/documents/product-information/nyxthracis-epar-product-information_mt.pdf)

Nederlands (NL) (1.14 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/nl/documents/product-information/nyxthracis-epar-product-information_nl.pdf)

norsk (NO) (1.08 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/no/documents/product-information/nyxthracis-epar-product-information_no.pdf)

polski (PL) (1.32 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/pl/documents/product-information/nyxthracis-epar-product-information_pl.pdf)

português (PT) (1.09 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/pt/documents/product-information/nyxthracis-epar-product-information_pt.pdf)

română (RO) (1.4 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/ro/documents/product-information/nyxthracis-epar-product-information_ro.pdf)

slovenčina (SK) (1.26 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/sk/documents/product-information/nyxthracis-epar-product-information_sk.pdf)

slovenščina (SL) (1.28 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/sl/documents/product-information/nyxthracis-epar-product-information_sl.pdf)

Suomi (FI) (1.12 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/fi/documents/product-information/nyxthracis-epar-product-information_fi.pdf)

svenska (SV) (1.08 MB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/sv/documents/product-information/nyxthracis-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0009 14/12/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Nyxthracis (previously Obiltoxaximab SFL) : EPAR - All authorised presentations

English (EN) (72.55 KB - PDF)

**First published:** 27/11/2020

**Last updated:** 09/09/2024

[View](/en/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-284)

български (BG) (87.47 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/bg/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_bg.pdf)

español (ES) (75.03 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/es/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_es.pdf)

čeština (CS) (78.26 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/cs/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (75.56 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/da/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (77.09 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/de/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (70.97 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/et/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (82.14 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/el/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_el.pdf)

français (FR) (73.97 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/fr/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (75.81 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/hr/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (77.57 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/is/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_is.pdf)

italiano (IT) (74.85 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/it/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (79.66 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/lv/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (78.16 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/lt/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (77.6 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/hu/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (81.82 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/mt/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (73.07 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/nl/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (80.13 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/no/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_no.pdf)

polski (PL) (79.97 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/pl/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_pl.pdf)

português (PT) (76.77 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/pt/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_pt.pdf)

română (RO) (77.29 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/ro/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (79.86 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/sk/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (76.2 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/sl/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (70.89 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/fi/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (73.9 KB - PDF)

**First published:**

27/11/2020

**Last updated:**

09/09/2024

[View](/sv/documents/all-authorised-presentations/nyxthracis-previously-obiltoxaximab-sfl-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Nyxthracis (previously Obiltoxaximab SFL) Active substance nyxthracis International non-proprietary name (INN) or common name obiltoxaximab Therapeutic area (MeSH) Anthrax Anatomical therapeutic chemical (ATC) code J06BB22

### Pharmacotherapeutic group

Immune sera and immunoglobulins

### Therapeutic indication

Obiltoxaximab SFL is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to Bacillus anthracis (see section 5.1).

Obiltoxaximab SFL is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/005169

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Marketing authorisation holder

SFL Pharmaceuticals Deutschland GmbH

Marie-Curie-Strasse 8 79539 Lörrach Germany

Opinion adopted 17/09/2020 Marketing authorisation issued 18/11/2020 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Nyxthracis (previously Obiltoxaximab SFL) : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (349.54 KB - PDF)

**First published:** 26/01/2022

**Last updated:** 09/09/2024

[View](/en/documents/procedural-steps-after/nyxthracis-previously-obiltoxaximab-sfl-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Obiltoxaximab SFL : EPAR - Public assessment report

Adopted

Reference Number: EMA/524933/2020

English (EN) (7.89 MB - PDF)

**First published:** 27/11/2020

**Last updated:** 09/09/2024

[View](/en/documents/assessment-report/obiltoxaximab-sfl-epar-public-assessment-report_en.pdf)

Obiltoxaximab SFL : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMA/OD/0000037218

English (EN) (592.6 KB - PDF)

**First published:** 27/11/2020

**Last updated:** 09/09/2024

[View](/en/documents/orphan-maintenance-report/obiltoxaximab-sfl-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

CHMP summary of positive opinion for Obiltoxaximab SFL

Adopted

Reference Number: EMA/CHMP/460994/2020

English (EN) (226.26 KB - PDF)

**First published:** 18/09/2020

**Last updated:** 09/09/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-obiltoxaximab-sfl_en.pdf)

#### News on Nyxthracis (previously Obiltoxaximab SFL)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020) 18/09/2020

#### More information on Nyxthracis

This product was originally [designated an orphan medicine](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2065) on 24 August 2018. Nyxthracis was withdrawn from the Community register of orphan medicinal products by the European Commission in August 2024 at the time of the withdrawal of the marketing authorisation.

**This page was last updated on** 09/09/2024

## Share this page

[Back to top](#main-content)